Tobacco SmokingTABATRANSPLANTNCT07050004
Prevalence of Smoking After Lung Transplantation
An observational study of Tobacco Smoking and Lung Transplantation, run by Fondation Hôpital Saint-Joseph at 1 site in France.
Trial summary
Smoking is one of the main risk factors for chronic obstructive pulmonary disease (COPD), the primary indication for lung transplantation (LT) in France. Resumption of smoking after transplantation is associated with an increased risk of graft dysfunction, neoplasia and reduced survival. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Tobacco Smoking, Lung Transplantation
- What is being tested?
- SMOKING
- Type of treatment
- Lifestyle or therapy programme
- How many people
- 1,099 participants
- Where
- 1 siteFrance
- Study dates
- 1 May 2023to 11 Dec 2024
- How long will I take part?
- 1 Day
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients who have benefited from a lung or cardiopulmonary transplantation
Who may be able to join
- Patient who has undergone a lung transplant (single, double or heart-lung) and is being followed up in a transplant centre in France;
- Age ≥ 18 years;
- French-speaking patient;
- Patient able to give his non-opposition.
Who cannot join
- Patient under guardianship or curatorship;
- Patient deprived of liberty ;
- Patient under court protection;
- Patients who object to the use of their data for this research.
Trial locations and contacts
1 site in 1 country.
About this study
Smoking is one of the main risk factors for chronic obstructive pulmonary disease (COPD), the primary indication for lung transplantation (LT) in France. Resumption of smoking after transplantation is associated with an increased risk of graft dysfunction, neoplasia and reduced survival. The prevalence of resumption of smoking after transplantation is based on few data available in the literature and is estimated at between 0 and 15%. The aim of this study is to determine the prevalence of smoking in transplantation. These results will enable healthcare professionalś to carry out information, education, prevention and support actions to help patients stop smoking throughout the transplantation process.
- Conditions
- Tobacco Smoking, Lung Transplantation
- Being tested
- SMOKING
- Medical subject headings
- Tobacco Smoking
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SMOKINGBehavioural
Patients who agree to take part in the study will complete a questionnaire covering the pre- and post-transplant aspects of smoking on their lifestyle
What is being measured
The primary outcome is the main question the study is designed to answer.
Assessing the prevalence of active smoking in post-lung transplantation sing a questionnaire
Proportion of transplant patients with active smoking
Measured: one year post transplantation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Jul 2025
- Study start1 May 2023
- Primary completion11 Jul 2024
- Study completion11 Dec 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Tobacco SmokingStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,099 participants (actual)
- Target duration
- 1 Day
Sponsor and investigators
- Lead sponsor
- Fondation Hôpital Saint-Joseph
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07050004
- Sponsor's protocol ID
- 2023-A00918-37
- Acronym
- TABATRANSPLANT
- Status last verified
- Jun 2025
- First submitted
- 18 Jun 2025
- Last updated
- 3 Jul 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prevalence of Smoking After Lung Transplantation
- ClinicalTrials.gov ID
- NCT07050004
- Acronym / sponsor ID
- TABATRANSPLANT / 2023-A00918-37
- Conditions
- Tobacco Smoking, Lung Transplantation
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1,099 participants (actual)
- Lead sponsor
- Fondation Hôpital Saint-JosephUniversity, hospital or other
- Study start
- 1 May 2023 (actual)
- Primary completion
- 11 Jul 2024 (actual)
- Study completion
- 11 Dec 2024 (actual)
- First posted
- 3 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Smoking is one of the main risk factors for chronic obstructive pulmonary disease (COPD), the primary indication for lung transplantation (LT) in France. Resumption of smoking after transplantation is associated with an increased risk of graft dysfunction, neoplasia and reduced survival. The prevalence of resumption of smoking after transplantation is based on few data available in the literature and is estimated at between 0 and 15%. The aim of this study is to determine the prevalence of smoking in transplantation. These results will enable healthcare professionalś to carry out information, education, prevention and support actions to help patients stop smoking throughout the transplantation process.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 1 Day
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients who have benefited from a lung or cardiopulmonary transplantation
Key inclusion criteria (4 listed)
- Patient who has undergone a lung transplant (single, double or heart-lung) and is being followed up in a transplant centre in France;
- Age ≥ 18 years;
- French-speaking patient;
- Patient able to give his non-opposition.
Key exclusion criteria (4 listed)
- Patient under guardianship or curatorship;
- Patient deprived of liberty ;
- Patient under court protection;
- Patients who object to the use of their data for this research.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SMOKINGPatients who agree to take part in the study will complete a questionnaire covering the pre- and post-transplant aspects of smoking on their lifestyle | Behavioural | – |
Primary outcome
Assessing the prevalence of active smoking in post-lung transplantation sing a questionnaire
Time frame: one year post transplantation
Proportion of transplant patients with active smoking
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Jul 2025.
Related trials for Tobacco Smoking
Active, not recruiting
Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS
COPD, Smoking
Enrolling by invitationObservational study
Using Smartwatches to Monitor Smoking in Real-life Situations
Smoking
Not yet recruitingObservational study
PROMETHEE: A Shared Interregional Tele-Tobacco Cessation Platform Embedded Within the IMPULSION Lung Cancer Screening Program
Smoking Cessation, Lung Cancer Screening
Recruiting
Effectiveness of Volitional Help Sheets as an Adjunct to Treatment to Promote Behavior Change: A Pilot Study on Smoking
Tobacco Dependence
Not yet recruiting
Impacto 2.0: Mobile Smoking Cessation Across Texas
Cigarette Smoking, Smoking Cessation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Tobacco Smoking and Lung Transplantation, run by Fondation Hôpital Saint-Joseph at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Assessing the prevalence of active smoking in post-lung transplantation sing a questionnaire (time frame: one year post transplantation). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Jul 2025.